Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

Go back to Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 TrialsĀ of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

February 1, 2021 7:30 AM EST

Roflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA SuccessFavorable safety and tolerability profile in this patient populationNew Drug Application (NDA) submission anticipated in the second half of... More